A new study conducted by IVI in collaboration with SK bioscience shows that single-dose and two-dose regimens of Vi-DT typhoid conjugate vaccine (TCV) are safe and immunogenic in children six to 23 months of age, a group with high rates of typhoid fever in resource-limited settings. The findings from this study, newly published online in